window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 13, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Oral Therapy

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    PhoreMost advances brain cancer candidate PMC-001 towards Phase 1

    PhoreMost has unveiled its lead oncology programme, PMC-001, as the [...]

    June 11, 2026
  • Uncategorised

    Pharvaris eyes 2026 filing as Phase 3 HAE trial timeline shifts

    Pharvaris has adjusted its guidance for topline results from its [...]

    July 10, 2025
  • Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development

    Oral hope for diabetic retinopathy: Breye completes positive Phase 1b trial of danegaptide

    Breye Therapeutics has announced the successful completion of its Phase [...]

    May 5, 2026
  • Clinical & Regulatory

    Orforglipron: Lilly’s first oral GLP 1 pill cuts A1C by up to 1.6% and trims 16 lbs in Phase 3 trial

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • OrganaBio to manufacture RxMP haemostatic therapy RMP-402
    Categories: Advanced Therapies, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics
  • Symeres expands spray drying capacity at New Jersey site to support poorly soluble small molecules
    Categories: Biotech & Pharma Business, Drug Delivery & Formulation, Drug Discovery & Development
  • Axplora consolidates UDCA manufacturing at Vizag site to strengthen integrated global supply and support future growth
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top